Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


30.12.2018

1 Anticancer Res
4 Biochem Biophys Res Commun
2 Cancer Res
1 Dig Dis
8 Hepatology
1 J Gastroenterol Hepatol
5 J Hepatol
2 Lancet Gastroenterol Hepatol
2 Oncogene
3 PLoS One
12 Transplant Proc


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. SEO S, Yoh T, Morino K, Fuji H, et al
    The Relationship Between (18)F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:341-346.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  2. YUTING Y, Lifeng F, Qiwei H
    Secreted modular calcium-binding protein 2 promotes high fat diet (HFD)-induced hepatic steatosis through enhancing lipid deposition, fibrosis and inflammation via targeting TGF-beta1.
    Biochem Biophys Res Commun. 2018 Dec 20. pii: S0006-291X(18)32649.
    PubMed     Text format     Abstract available

  3. LU S, Lu H, Jin R, Mo Z, et al
    Promoter methylation and H3K27 deacetylation regulate the transcription of VIPR1 in hepatocellular carcinoma.
    Biochem Biophys Res Commun. 2018 Dec 21. pii: S0006-291X(18)32788.
    PubMed     Text format     Abstract available

  4. YAN C, Yang Q, Gong Z
    Transgenic expression of tgfb1a induces hepatic inflammation, fibrosis and metastasis in zebrafish.
    Biochem Biophys Res Commun. 2018 Dec 20. pii: S0006-291X(18)32747.
    PubMed     Text format     Abstract available

  5. WANG B, Xian J, Zang J, Xiao L, et al
    Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression.
    Biochem Biophys Res Commun. 2018 Dec 17. pii: S0006-291X(18)32740.
    PubMed     Text format     Abstract available


    Cancer Res

  6. DONG Q, Du Y, Li H, Liu C, et al
    EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma.
    Cancer Res. 2018 Dec 20. pii: 0008-5472.CAN-18-1273.
    PubMed     Text format     Abstract available

  7. CHEN SL, Zhang CZ, Liu LL, Lu SX, et al
    A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related hepatocellular carcinoma.
    Cancer Res. 2018 Dec 24. pii: 0008-5472.CAN-18-2357.
    PubMed     Text format     Abstract available


    Dig Dis

  8. SHIRIN D, Peleg N, Sneh-Arbib O, Cohen-Naftaly M, et al
    The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities.
    Dig Dis. 2019;37:69-76.
    PubMed     Text format     Abstract available


    Hepatology

  9. BILL R, Montani M, Blum B, Dufour JF, et al
    Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver.
    Hepatology. 2018;68:384-386.
    PubMed     Text format    

  10. SHIFFMAN ML, Sussman NL, Ravendhran N, Ditmyer M, et al
    Financial compensation for hepatologists in different practice settings.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30488.
    PubMed     Text format     Abstract available

  11. KANWAL F, Tapper EB, Ho C, Asrani SK, et al
    Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30489.
    PubMed     Text format     Abstract available

  12. ORNOLFSSON KT, Olafsson S, Bergmann OM, Gershwin ME, et al
    Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29675.
    PubMed     Text format     Abstract available

  13. CAI Y, Li H, Liu M, Pei Y, et al
    Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity.
    Hepatology. 2018;68:48-61.
    PubMed     Text format     Abstract available

  14. ORLIEN SMS, Sandven I, Berhe NB, Ismael NY, et al
    Khat chewing increases the risk for developing chronic liver disease: A hospital-based case-control study.
    Hepatology. 2018;68:248-257.
    PubMed     Text format     Abstract available

  15. HUYNH H, Lee LY, Goh KY, Ong R, et al
    Infigratinib mediates vascular normalization, impairs metastasis and improves chemotherapy in hepatocellular carcinoma.
    Hepatology. 2018 Dec 21. doi: 10.1002/hep.30481.
    PubMed     Text format     Abstract available

  16. MOORE A, Wu L, Chuang JC, Sun X, et al
    Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation.
    Hepatology. 2018 Dec 25. doi: 10.1002/hep.30487.
    PubMed     Text format     Abstract available


    J Gastroenterol Hepatol

  17. TOBARI M, Hashimoto E, Taniai M, Ikarashi Y, et al
    Characteristics of nonalcoholic steatohepatitis among lean patients in Japan: not uncommon and not always benign.
    J Gastroenterol Hepatol. 2018 Dec 27. doi: 10.1111/jgh.14585.
    PubMed     Text format     Abstract available


    J Hepatol

  18. ZHANG YM, Zhou ZT, Liu GM
    Factors predicting early recurrence after surgical resection of hepatocellular carcinoma.
    J Hepatol. 2018 Dec 19. pii: S0168-8278(18)32523.
    PubMed     Text format    

  19. CHAN AWH, Berhane S, Cucchetti A, Johnson PJ, et al
    Reply to: Correspondence concerning "Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection".
    J Hepatol. 2018 Dec 18. pii: S0168-8278(18)32577.
    PubMed     Text format    

  20. BAUMEISTER SE, Schlesinger S, Aleksandrova K, Jochem C, et al
    Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633.
    PubMed     Text format     Abstract available

  21. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32635.
    PubMed     Text format     Abstract available

  22. MOHKAM K, Mabrut JY
    Reply to: "Treatment for solitary hepatocellular carcinoma ranging from 2 and 5cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?"
    J Hepatol. 2018 Dec 24. pii: S0168-8278(18)32579.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  23. EZAZ G, Tapper EB
    Driving in the dark: cirrhosis in young adults.
    Lancet Gastroenterol Hepatol. 2018 Dec 17. pii: S2468-1253(18)30419.
    PubMed     Text format    

  24. FLEMMING JA, Dewit Y, Mah JM, Saperia J, et al
    Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study.
    Lancet Gastroenterol Hepatol. 2018 Dec 17. pii: S2468-1253(18)30339.
    PubMed     Text format     Abstract available


    Oncogene

  25. CORTES E, Lachowski D, Rice A, Thorpe SD, et al
    Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor.
    Oncogene. 2018 Dec 21. pii: 10.1038/s41388-018-0631.
    PubMed     Text format     Abstract available

  26. LAOUIREM S, Sannier A, Norkowski E, Cauchy F, et al
    Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome.
    Oncogene. 2018 Dec 21. pii: 10.1038/s41388-018-0597.
    PubMed     Text format     Abstract available


    PLoS One

  27. CHANG PE, Goh GBB, Leow WQ, Shen L, et al
    Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0199166.
    PubMed     Text format     Abstract available

  28. CALLE RUBIO M, Soriano JB, Lopez-Campos JL, Soler-Cataluna JJ, et al
    Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.
    PLoS One. 2018;13:e0198777.
    PubMed     Text format     Abstract available

  29. TSAI WC, Kung PT, Wang YH, Kuo WY, et al
    Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer.
    PLoS One. 2018;13:e0199532.
    PubMed     Text format     Abstract available


    Transplant Proc

  30. LEE HA, Cho EY, Kim TH, Lee Y, et al
    Risk Factors for Dropout From the Liver Transplant Waiting List of Hepatocellular Carcinoma Patients Under Locoregional Treatment.
    Transplant Proc. 2018;50:3521-3526.
    PubMed     Text format     Abstract available

  31. YEN YH, Kuo FY, Lin CC, Chen CL, et al
    Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter.
    Transplant Proc. 2018;50:3533-3538.
    PubMed     Text format     Abstract available

  32. OZER A, Aktas H, Eren N, Karakayali H, et al
    Hepatic Arterial Reconstruction Using Right Gastroepiploic Artery in Living Donor Liver Transplantation.
    Transplant Proc. 2018;50:3559-3561.
    PubMed     Text format     Abstract available

  33. TAN EK, Goh BKP, Lee SY, Krishnamoorthy TL, et al
    Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Transplant Proc. 2018;50:3564-3570.
    PubMed     Text format     Abstract available

  34. YILMAZ C, Karaca CA, Iakobadze Z, Farajov R, et al
    Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma.
    Transplant Proc. 2018;50:3571-3576.
    PubMed     Text format     Abstract available

  35. DAOUD A, Teeter L, Ghobrial RM, Graviss EA, et al
    Transplantation for Hepatocellular Carcinoma: Is There a Tumor Size Limit?
    Transplant Proc. 2018;50:3577-3581.
    PubMed     Text format     Abstract available

  36. HARIMOTO N, Nakagawara H, Shirabe K, Yoshizumi T, et al
    Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver.
    Transplant Proc. 2018;50:3858-3862.
    PubMed     Text format     Abstract available

  37. ESPOSITO A, Vit A, Adani G, Baccarani U, et al
    Indigo Thrombectomy System for Hepatic Artery Thrombosis After Liver Transplantation: A Case Report.
    Transplant Proc. 2018;50:4000-4003.
    PubMed     Text format     Abstract available

  38. TAN Z, Zhang W, Li G, Huang X, et al
    A Successful Case of Liver Transplantation in an Adult With Congenital Hepatic Arteriovenous Fistulae Associated Cardiac Dilatation and Heart Failure.
    Transplant Proc. 2018;50:4004-4007.
    PubMed     Text format     Abstract available

  39. HANNA RM, Selamet U, Hasnain H, El-Masry M, et al
    Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report.
    Transplant Proc. 2018;50:4033-4037.
    PubMed     Text format     Abstract available

  40. YU Z, Liu W, Deng Y, Yao J, et al
    Significant Efficacy of Apatinib in a Patient With Hepatocellular Carcinoma Lung Metastases After Liver Transplantation: A Case Report.
    Transplant Proc. 2018;50:4042-4045.
    PubMed     Text format     Abstract available

  41. LEE JG, Lee JI, Kim JY, Cho Y, et al
    Coculture With Ischemia/Reperfusion-Preconditioned Hepatocytes Improves Islet Function and Survival.
    Transplant Proc. 2018;50:3887-3894.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: